Clinical trial
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously…
NCT02626962 · Grupo Español Multidisciplinar de Melanoma, Other · Completed
Key facts
| NCT number | NCT02626962 |
|---|---|
| Title | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma |
| Official title | Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma |
| Acronym | GEM1402 |
| Lead sponsor | Grupo Español Multidisciplinar de Melanoma, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Uveal Melanoma |
| Intervention type | Drug |
| Interventions | ipilimumab, Nivolumab |
| Enrollment | 52 |
| Start date | Apr 1, 2016 |
| Primary completion | May 1, 2017 |
| Completion | Jul 22, 2021 |
| First posted | Dec 10, 2015 |
| Last update posted | Mar 22, 2022 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: